|
|
|
|
|
|
Portfolio Optimization: Health Advances was brought in by the new CEO of an early-stage pharmaceutical company to help optimize the
company's R&D portfolio. The company was focused on treatments for genetic diseases. Health Advances screened over 100 genetic diseases
on the basis of technical and commercial criteria to prioritize the company's portfolio and create a clinical development plan to generate
maximum value. The project also included an analysis of the company's operational capabilities that identified the human and capital
resources needed to execute the portfolio strategy.
Product Valuation: Health Advances was asked to provide a detailed market analysis and product concept refinement for two early-stage
next-generation supportive-care oncology products. Health Advances spoke with hematologists and medical oncologists in US, Europe, and
Japan to map current treatment pathways for chemotherapy and bone marrow/stem cell transplant patients, estimate potential patient populations,
determine dosing and pricing estimates, and identify red flags in the product concepts for each of the different geographies. Once the market
was sufficiently characterized, Health Advances used this knowledge to forecast the products' potential costs and revenues. Health Advances
used this information to drive a Monte Carlo analysis and generate a risk-adjusted NPV model.
Due Diligence: A leading venture capital firm was considering an investment in a private company that was developing a novel controlled-release
drug delivery system with applicability across a number of therapeutic areas. Health Advances was asked to evaluate the commercial potential of the
company's later-stage products as part of the due diligence process. Using primary and secondary research, Health Advances analyzed the potential
value created by these products, assessed the company's clinical trials, and characterized the competitive landscape.
Commercialization Strategy: We developed a complete commercialization strategy for a novel chemotherapeutic agent starting with analysis of the
indications, product positioning, and market potential and leading through the clinical trial plan and finishing with the partnership strategy.
Technology Evaluation: With a significant investment in the siRNA field, our client faced the challenging question of which of the many possible
indications to move into development. We agreed on which indications would lead to a clearly differentiated product profile and determined which
other applications to partner or to hold on to for future development.
Crohn's and Ulcerative Colitis: With a large number of compounds in the pipeline, our client was facing a challenging question regarding the
proper focus and development path for a new mechanistic approach involving the th1 and th2 immune response. Combining commercial and
competitive issues with an assessment of the development hurdles, we were able help the client finalize a set of development priorities and
confirm the investment required to complete development of their compound.
|
|
 |
|
|
|
|
